Issue Archive

Ivosidenib is a specific inhibitor of the mutant IDH1 enzyme that drives a subset of acute myeloid leukemias. This Plenary Paper is the first publication of safety and efficacy data for ivosidenib in newly diagnosed patients unfit for induction chemotherapy. Roboz and colleagues report sustained complete remissions in a substantial minority of patients. These data underpin the recent Food and Drug Administration approval for ivosidenib for this group of patients.

In this timely review, Miltiadous and colleagues highlight the importance of precise diagnosis of refractory immune thrombocytopenia (ITP) and comprehensively summarize the literature on treatment.

This prospective open-label study of dabigatran in children for secondary prophylaxis against venous thromboembolism (VTE) reveals low rates of recurrence and clinically significant bleeding over durations up to 1 year. The data suggest that dabigatran is safe for extended treatment of VTE in children and does not require routine laboratory monitoring.

Ruella and colleagues report their novel strategy for tackling the twin problems of undesirable transduction of an anti-CD19 chimeric antigen receptor (CAR) into malignant cells and the unnecessary persistence of CD19 CAR T cells in patients cured of their underlying tumor. Their cellular antidote is a CAR T cell against CAR19, and it is effective in resolving both problems in preclinical testing.

In this Letter to Blood, Strati and colleagues report that depth of response is associated with durability of benefit in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Patients who achieve a complete remission have longer durations of response than those with partial response. The authors provide preliminary evidence associating tumor-associated macrophages with depth of treatment response.